9th Circ. Backs Class Cert. In Suit Over Diabetes Drug Risk
By Patrick Hoff · June 17, 2025, 5:32 PM EDT
The Ninth Circuit refused to disband a class of third-party payors who claim Takeda Pharmaceutical and Eli Lilly & Co. hid their anti-diabetes drug's bladder cancer risks, finding no issue with...
To view the full article, register now.